Doral (quazepam)

Dosage of quazepam must be individualized, and the smallest effective dosage should be used (especially in geriatric or debilitated patients). Prolonged administration of quazepam should be avoided. Because of the drug's long elimination half-life, intermittent therapy (e.g., every second or third night) may be possible without substantial risk of rebound insomnia in some patients.

The usual adult dose of quazepam is 15 mg; a dose of 7.5 mg may be adequate for some patients. While a quazepam dose of 30 mg occasionally has been used, this dose is associated with an increased risk of daytime sedation. In geriatric or debilitated patients, an initial dose of 7.5 or 15 mg should be used; in patients receiving 15 mg initially, reduction of the dose after the first one or two nights of therapy should be attempted. In patients who have received prolonged (e.g., even for periods as brief as 6 weeks) quazepam therapy, abrupt discontinuance of the drug should be avoided since manifestations of withdrawal can be precipitated; if the drug is to be discontinued in such patients, it is recommended that dosage be gradually tapered.

Quazepam is administered orally at bedtime.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

A boxed warning has been included in the prescribing information for all benzodiazepines describing the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions associated with all drugs in this class. Abuse and misuse can result in overdose or death, especially when benzodiazepines are combined with other medicines, such as opioid pain relievers, alcohol, or illicit drugs. Frequent follow-up with patients receiving benzodiazepines is important. Reassess patients regularly to manage their medical conditions and any withdrawal symptoms. Clinicians should assess a patient's risk of abuse, misuse, and addiction. Standardized screening tools are available (https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools- resources/chart-screening-tools). To reduce the risk of acute withdrawal reactions, use a gradual dose taper when reducing the dosage or discontinuing benzodiazepines. Take precautions when benzodiazepines are used in combination with opioid medications.

Quazepam shares the toxic potentials of the benzodiazepines, and the usual precautions of benzodiazepine administration should be observed. (See Cautions in the Benzodiazepines General Statement 28:24.08.)

No enhanced messaging available.

Benzodiazepines can cause fetal harm when administered to pregnant women (see Cautions: Pregnancy and Lactation in the Benzodiazepines General Statement 28:24.08), and those used solely as hypnotics, such as quazepam, are contraindicated during pregnancy. The safety of quazepam during labor or delivery has not been established.

Quazepam and its metabolites are distributed into milk in humans. (See Pharmacokinetics: Distribution.) Therefore, use of the drug in nursing woman is not recommended.

No enhanced messaging available.